Pharmaceutical giant Eli Lilly has revealed plans for a further €927 million investment at its Raheen facility in Limerick, which will generate an additional 150 jobs.
This follows a similar investment last year to establish the state-of-the-art manufacturing site.
The Raheen facility is focused on producing biologic active ingredients, specifically for treatments aimed at Alzheimer’s disease. The initial investment, announced last year, was expected to create 300 jobs as the site develops its production capabilities.
With this latest investment, Lilly aims to significantly boost production capacity at the Limerick site. The company highlighted that this expansion is the most ambitious in its history, underscoring the strategic importance of the facility.
The combined investments will bring total employment at the Raheen plant to 450 once it begins operations next summer.